CYCC.Cyclacel Pharmaceuticals, INC

S-1: Cyclacel Pharmaceuticals Files for Resale of 15.2 Million Shares of Common Stock

Sentiment:

S-1 Filing

đź“‹All filings for Cyclacel Pharmaceuticals, INC
đź”’Login to Follow

Cyclacel Pharmaceuticals has filed a registration statement for the resale of up to 15,204,972 shares of its common stock by selling stockholders.

Capital raiseThe company recently completed a private placement, selling shares and warrants for gross proceeds of approximately $8.0 million.The company may receive additional capital from the exercise of outstanding warrants.
Worse than expectedThe company's stockholders' equity was $607,000 as of December 31, 2023, and the company must submit a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1).

Summary

  • Cyclacel Pharmaceuticals has filed a Form S-1 registration statement with the SEC to allow selling stockholders to offer and resell up to 15,204,972 shares of the company's common stock.
  • These shares consist of 145,000 shares issued in a private placement on May 2, 2024, shares issuable upon exercise of pre-funded warrants (4,823,945 shares), Series A warrants (4,968,945 shares), Series B warrants (4,968,945 shares), and placement agent warrants (298,137 shares).
  • The company will not receive any proceeds from the sale of these shares by the selling stockholders, but will receive proceeds from the cash exercise of warrants.
  • The selling stockholders may offer these shares from time to time through public or private transactions at fixed, prevailing market, related to market, varying, or negotiated prices.
  • As of May 3, 2024, Cyclacel had 1,463,259 shares of common stock outstanding.
  • The company's stock is traded on The Nasdaq Capital Market under the symbol CYCC, with the last reported sale price on May 3, 2024, at $2.00 per share.
  • The company intends to use the proceeds from any warrant exercises for general corporate purposes and working capital.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company is enabling resale of shares and could receive proceeds from warrant exercises, there are concerns about Nasdaq compliance and potential stock price decline due to selling pressure.

Positives

  • The registration statement allows selling stockholders to resell their shares, potentially increasing liquidity for investors.
  • Cyclacel could receive proceeds from the exercise of warrants, which would be used for general corporate purposes and working capital.

Negatives

  • The company will not receive any proceeds from the sale of shares by the selling stockholders.
  • A substantial sale of shares by stockholders could cause the price of the common stock to decline.
  • The company's stockholders' equity was $607,000 as of December 31, 2023, and the company must submit a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1).
  • The company may not be able to continue its current listing of its common stock on the Nasdaq Capital Market.

Risks

  • The company may not be able to continue its current listing on the Nasdaq Capital Market due to not meeting the minimum stockholders' equity requirement.
  • A delisting from Nasdaq could limit the liquidity of the stock, increase its volatility, and hinder the company's ability to raise capital.
  • Sales of a substantial number of shares by stockholders may cause the price of the common stock to decline.
  • The company's success depends on the clinical trials of its drug candidates, fadraciclib and plogosertib.

Future Outlook

The company expects to use the proceeds received from the exercise of the Warrants or Placement Agent Warrants, if any, for general corporate purposes and working capital.

Industry Context

Cyclacel is a clinical-stage biopharmaceutical company focused on developing cancer medicines. The company's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications.

Comparison to Industry Standards

  • The document does not contain specific comparisons to industry standards.
  • However, it mentions Cyclacel's focus on developing cancer medicines, placing it within the competitive landscape of other pharmaceutical companies in the oncology space, such as Pfizer, Novartis, and Roche.
  • The company's approach of targeting cell cycle, transcriptional regulation, epigenetics, and mitosis biology aligns with current trends in cancer research and drug development.

Stakeholder Impact

  • Shareholders may experience stock price volatility due to potential sales by selling stockholders.
  • The company's ability to fund operations and research and development could be affected by its Nasdaq listing status and ability to raise capital.
  • Employees may be affected by the company's financial performance and ability to continue operations.

Next Steps

  • Selling stockholders may offer and sell their shares.
  • The company will prepare and file a registration statement covering the Securities on or prior to the date that is 15 calendar days following the date of the Registration Rights Agreement.
  • The company will use its best efforts to cause the registration statement covering the Registrable Securities to be declared effective as promptly as practicable after the filing thereof, but in any event no later the 45th calendar day following the date of the Registration Rights Agreement (or in the event of a full review by the SEC, the 75th calendar day following the date of the Registration Rights Agreement).

Key Dates

DateDescription
August 1997Cyclacel Pharmaceuticals, Inc. was incorporated in Delaware.
November 3, 2004Board of directors designated 2,046,813 shares of preferred stock that were issued as convertible preferred stock.
November 1, 2005Company may exchange the convertible preferred stock in whole, but not in part, for debentures on any dividend payment date on or after this date.
November 3, 2007On or after this date, the company may not elect to automatically convert the convertible preferred stock if full cumulative dividends on the convertible preferred stock for all past dividend periods have not been paid or set aside for payment.
July 21, 20178,872 shares of the Company's Series A Preferred Stock were issued in a underwritten public offering.
December 18, 2020237,745 shares of the Company's Series B Preferred Stock were issued in connection with a registered direct offering.
December 15, 2023Reverse stock split of outstanding common stock became effective at 5:00 p.m. Eastern Time.
December 21, 2023Company entered into a securities purchase agreement with certain institutional investors.
March 27, 2024Company received a written notice from Nasdaq indicating non-compliance with Nasdaq Listing Rule 5550(b)(1).
April 29, 2024Date of Securities Purchase Agreement between the Company and the purchaser.
April 30, 2024Company entered into a securities purchase agreement with an institutional accredited investor.
May 2, 2024Private placement of 145,000 shares of common stock.
May 3, 2024Last reported sale price of common stock was $2.00 per share.
May 6, 2024Date of the prospectus.
May 10, 2024Deadline to submit a plan to Nasdaq to regain compliance with Nasdaq Listing Rule 5550(b)(1).

Keywords

common stock, warrants, resale, registration statement, selling stockholders, private placement, CYCC, Cyclacel Pharmaceuticals, securities, offering

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.